Prosecutors say the Las Vegas businessman used Protectus companies, reimbursement-linked rebates, and a multistate sales network to funnel alleged kickbacks through government-funded wound-care claims during the 2026 National Health Care Fraud Takedown campaign.
WASHINGTON, DC — Federal prosecutors have indicted Michael McMillan, a 55-year-old Las Vegas businessman, in an alleged $268 million healthcare fraud and kickback scheme involving costly skin-substitute products billed to Medicare, TRICARE, and another federal program serving military families.
The nine-count federal indictment, filed in the Northern District of Texas and announced during the 2026 National Health Care Fraud Takedown, accuses McMillan of constructing a reimbursement-driven business model that allegedly rewarded medical providers and sales representatives whenever government programs paid wound-care claims.
According to the official case announcement from the Northern District of Texas, prosecutors allege that McMillan owned Protectus LLC and related companies, offered skin-substitute products through unlawful kickback arrangements, and received approximately $174 million after federal healthcare programs paid the disputed claims.
No allegation in the indictment has been proven at trial, and McMillan remains presumed innocent unless prosecutors establish every charged offense beyond a reasonable doubt through admissible evidence before a jury or unless the case ends through another lawful resolution.
A Seven-Year Scheme Alleged by Prosecutors
The indictment places the alleged conduct between approximately May 2019 and at least February 2026, describing a long-running operation that connected a Nevada-controlled product network with physicians, podiatrists, a nurse practitioner, sales representatives, and beneficiaries located across Texas, California, Utah, and elsewhere.
Prosecutors identify six Nevada limited-liability companies allegedly owned and controlled by McMillan, including Protectus LLC, Protectus Technologies LLC, Protectus Consulting LLC, Prestige Medical Consultants LLC, Velare Wound Care LLC, and Amnio ReGen Solutions LLC, which the charging document collectively describes as Protectus.
Rather than publicly naming the medical providers or sales representatives as defendants in McMillan’s indictment, the grand jury document labels five clinicians as Medical Providers A through E and four sales participants as Individuals A through D while describing their locations and alleged functions.
Those clinicians allegedly included an Arlington physician, a Santa Monica podiatrist, a Dallas nurse practitioner, a McKinney podiatrist, and a Payson, Utah, podiatrist, whose wound-care claims became examples supporting the government’s broader theory about price disclosures and financial inducements.
Skin Substitutes and Government Reimbursement
Skin substitutes, sometimes called cellular or tissue-based products, allografts, or wound grafts, are bioengineered products placed over open wounds to encourage closure or skin growth, and government programs generally reimburse covered applications only when the products and related treatment are medically necessary.
Because reimbursement can be calculated by the square centimeter, the total payment associated with a single application may rise substantially when larger products or repeated treatments are billed, creating an unusually sensitive relationship among acquisition cost, documented wound size, utilization, and the amount claimed.
The indictment does not merely criticize high prices or aggressive selling, because its central allegation is that Protectus linked product charges directly to successful government reimbursement while allowing providers to keep a predetermined share that prosecutors characterize as an illegal kickback rather than a lawful discount.
That distinction will matter throughout the litigation, since healthcare businesses may offer legitimate discounts under carefully structured circumstances, while federal law generally prohibits knowingly offering or paying remuneration intended to induce purchases, orders, or recommendations involving items reimbursable by federal healthcare programs.
How the Alleged Reimbursement Split Worked
Prosecutors allege that Protectus supplied skin-substitute products to participating providers without requiring upfront payment, waited until a government program reimbursed the corresponding claim, and declined to charge the provider whenever Medicare, TRICARE, or CHAMPVA refused reimbursement for the product.
Once a claim was paid, the indictment says Protectus ordinarily invoiced the clinician for between 60 and 70 percent of the reimbursement, leaving the clinician with between 30 and 40 percent and allegedly guaranteeing thousands of dollars in profit on every successful claim.
That contingent structure allegedly shifted denial risk away from providers while making their retained compensation depend on government payment, a combination prosecutors say turned routine product distribution into an inducement designed to influence which skin substitutes clinicians ordered and applied.
McMillan and Protectus employees also allegedly billed on behalf of providers or helped them submit claims, giving the product companies visibility into reimbursement decisions, invoice timing, disclosed acquisition prices, and the precise amounts available for division after federal programs released payment.
Box 19 and the Alleged Price Misrepresentation
The indictment says providers were required to disclose the actual price paid for skin substitutes, including discounts, rebates, refunds, and other adjustments, through information placed in Box 19 of the Medicare claim, rather than reporting a higher figure disconnected from the transaction’s economic reality.
Prosecutors accuse McMillan and Protectus of submitting, or counseling providers to submit, an inflated price that did not reflect what clinicians actually paid after the reimbursement-linked reduction, thereby concealing the alleged profit split from program administrators evaluating the claims.
This alleged misrepresentation is essential to the prosecution theory because the government must prove more than an unconventional commercial arrangement; it must show that participants knowingly used materially false pretenses or promises to obtain federal healthcare money in connection with covered products and services.
Defense litigation could therefore examine whether claim instructions were clear, who supplied each disputed price, how contractual terminology described the reductions, whether providers understood their disclosure duties, and whether the government can connect McMillan personally to material falsehoods across a sprawling network.
Invoices and Emails Cited by the Grand Jury
One invoice dated October 31, 2022, allegedly showed that Medical Provider E collected $53,625.60, kept $16,087.68, and owed Protectus Technologies LLC $37,537.92, producing the exact 30-to-70 allocation that prosecutors describe as evidence of a reimbursement-sharing arrangement.
Another episode from July 2023 allegedly began when an employee for Medical Provider A challenged an invoice because a newer agreement provided the clinician with 40 percent profit while the attachment reflected only 35 percent, prompting McMillan to direct that the document be corrected.
The indictment also describes a March 2024 meeting during which McMillan allegedly explained that Protectus offered providers an average 35 percent rebate, illustrating that a clinician collecting $180,000 monthly from Medicare skin-substitute claims could retain approximately $63,000 under the arrangement.
During that same meeting, prosecutors say McMillan claimed that he reviewed every Medicare submission to ensure Protectus products were billed at a higher price than providers actually paid, an alleged statement likely to receive close attention as lawyers debate knowledge, intent, context, and accuracy.
In May 2024, after Medicare reportedly paid Medical Provider D $9,024 for one claim and denied another, a Protectus employee allegedly identified missing Box 19 information, advised resubmission, and issued a $5,865.60 invoice equal to 65 percent of the paid claim.
Sales Representatives and Alleged Referral Payments
The government further alleges that McMillan hired sales representatives to recruit clinicians, instructed them to explain the profit-sharing formula, and based their compensation directly on reimbursements generated by medical providers they brought into the Protectus distribution network.
After a clinician received reimbursement and paid Protectus its 60-to-70-percent share, the indictment says McMillan paid the responsible representative a percentage of Protectus’s receipt, thereby allegedly connecting representative compensation to referrals involving products reimbursed by federal healthcare programs.
Prosecutors estimate that Protectus paid approximately $27 million in alleged kickbacks to sales representatives, in addition to approximately $94 million allegedly paid to medical providers, figures that illustrate how deeply the government believes financial inducements were embedded within the company’s growth strategy.
One November 2022 email exchange allegedly concerned a disputed representative commission report worth $44,035.92, including a claimed $6,446.55 omission, while a Protectus employee responded that commissions could be paid only after the company learned that an insurer had reimbursed the provider.
Approximately $268 Million Paid, Prosecutors Say
Across the full alleged scheme, McMillan and Protectus allegedly caused Medicare and other federal healthcare programs to pay approximately $268 million for skin-substitute claims, with Protectus receiving roughly $174 million after participating providers retained their negotiated percentages from successful reimbursements.
The figures represent alleged program payments rather than a final judicial loss calculation, and any eventual sentencing analysis could involve contested evidence concerning legitimate services, medically necessary treatment, product value, patient benefit, overlapping transactions, recovered property, and the legal definition of attributable loss.
The indictment’s reach beyond Medicare is also significant because TRICARE covers eligible active-duty personnel, retirees, family members, and survivors, while CHAMPVA shares covered healthcare costs for qualifying spouses or children of veterans with certain service-connected disabilities or deaths.
By alleging harm across those programs, prosecutors portray the case as an attack not only upon public funds but also upon healthcare systems serving elderly or disabled beneficiaries, military communities, and veterans’ families who depend upon reliable administration of limited federal resources.
Nine Counts and Seven Financial Transactions
Count One charges conspiracy to commit healthcare fraud, alleging that McMillan and others agreed to obtain federal healthcare money through materially false representations connected with skin-substitute claims, while Count Two charges conspiracy to defraud the United States and pay healthcare kickbacks and bribes.
Counts Three through Nine charge McMillan with engaging in monetary transactions exceeding $10,000 using property allegedly derived from specified unlawful activity, focusing on seven purchases or transfers that prosecutors say moved proceeds generated through the charged conspiracies.
The listed transactions include payments connected with residential properties in Dallas, Las Vegas, Kentucky, and Del Mar, California, along with a 2023 Lamborghini Urus, a 2023 Cadillac Escalade, and a 1997 Cessna Citation VII private aircraft.
The aircraft transaction, dated September 2025 and valued in the indictment at approximately $2.56 million, allegedly originated from an account associated with Elite Elevated Enterprises LLC, while the property-related transactions ranged from approximately $260,466 to $1.3 million.
These transaction counts do not independently prove that any asset was purchased with criminal proceeds, because prosecutors must establish the required connection, McMillan’s knowledge that the property was criminally derived, and every remaining statutory element beyond a reasonable doubt.
Homes, Vehicles, Aircraft, and Forfeiture
The charging document alleges that McMillan used proceeds to finance a lavish lifestyle involving houses, condominiums, luxury vehicles, and a private jet, while the Justice Department separately reported that authorities seized assets valued at approximately $35 million during the investigation.
Its forfeiture notice identifies real property in Simpsonville, Kentucky; Dallas, Texas; Del Mar, California; and two Las Vegas locations, and seeks a money judgment representing alleged gross proceeds traceable to the offenses if McMillan is ultimately convicted.
Forfeiture language in an indictment notifies the defendant of the property the government intends to pursue, but it does not constitute a final forfeiture order, and ownership interests, tracing questions, third-party claims, substitute-asset rules, and proportionality arguments may remain subject to later proceedings.
The distinction between seizure and permanent forfeiture remains important, because seizure places property under governmental control during litigation, whereas title generally becomes permanently forfeited only through an applicable legal process supported by the necessary findings, admissions, or judicial orders.
Part of the 2026 National Health Care Fraud Takedown
McMillan’s prosecution emerged from the 2026 National Health Care Fraud Takedown, a coordinated federal and state initiative that charged 455 defendants, including 90 doctors and other licensed medical professionals, over alleged schemes collectively involving more than $6.5 billion in false claims.
An Associated Press report on the nationwide healthcare fraud crackdown described cases involving unnecessary wound procedures, fraudulent hospice enrollment, cardiovascular testing, and services allegedly never delivered, demonstrating how authorities paired financial-loss allegations with claims of direct patient harm.
Federal officials said the broader campaign stretched across 56 federal districts and 45 states and territories, involved all 50-state Medicaid Fraud Control Units, and produced seizures exceeding $182 million in cash, vehicles, jewelry, and other property during coordinated enforcement activity.
Administrative measures accompanied the criminal cases, with the Centers for Medicare and Medicaid Services suspending 1,079 providers and revoking billing privileges for 1,403 providers, reflecting an enforcement model intended to stop questionable payments while prosecutors develop courtroom cases.
Northern District of Texas Cases Exceed $365 Million
Within the Northern District of Texas, federal prosecutors announced charges against 13 defendants across seven cases involving more than $365 million in alleged fraudulent billing submitted to government-funded programs and other insurers, making McMillan’s case the district’s largest announced matter by dollar value.
The district’s other prosecutions addressed allegations involving laboratory testing, transcranial magnetic stimulation, electroencephalography, hospice care, unsolicited COVID-19 test kits, and durable medical equipment, showing that investigators targeted multiple reimbursement channels rather than a single product category.
Investigators assigned to the McMillan matter include the FBI’s Dallas Field Office, the Department of Health and Human Services Office of Inspector General, the Defense Criminal Investigative Service, and the Department of Veterans Affairs Office of Inspector General.
Assistant United States Attorneys Marty Basu and Chad Meacham are prosecuting the case, according to the Justice Department, placing the criminal litigation within a district that has increasingly emphasized data analysis, interagency cooperation, asset tracing, and accountability for providers and corporate actors.
Why the Case Matters to the Wound-Care Industry
For wound-care companies and clinicians, the allegations underline how commercial terms can become criminal evidence when discounts are tied to referrals, profit promises track federal reimbursement, claim forms allegedly conceal net acquisition prices, and representatives receive compensation generated by federally reimbursed orders.
Compliance programs must therefore evaluate economic substance rather than labels alone, because calling a payment a rebate, discount, commission, consulting fee, or marketing expense will not necessarily protect an arrangement when documents, emails, invoices, and conduct suggest unlawful inducement.
Providers also face heightened risk when vendors control billing assistance, since convenient support can blur responsibility for codes and price disclosures, leaving clinicians exposed if submissions contain information they did not independently verify against contracts, invoices, adjustments, and applicable program requirements.
The case also shows why boards, executives, and professional practices should preserve communications and obtain qualified legal advice when questions arise, because improvised explanations, retroactive invoice changes, deleted records, or inconsistent public statements can create additional investigative and reputational complications.
Organizations confronting public allegations may need disciplined reputation rebuilding strategies that distinguish verified facts from accusations, correct misinformation without obstructing legal proceedings, and maintain consistent communications with employees, patients, partners, regulators, and journalists throughout a prolonged case.
Legal Exposure and the Road Ahead
The conspiracy, kickback, and monetary-transaction allegations expose McMillan to potentially substantial penalties if convicted, although any sentence would depend upon the statutes of conviction, advisory guidelines, judicial findings, criminal history, accepted responsibility, loss disputes, and other individualized factors.
Before trial, the parties may litigate discovery, expert evidence, search-and-seizure questions, financial tracing, healthcare billing rules, witness credibility, and the admissibility of communications, while prosecutors retain the burden of proving criminal intent rather than relying solely on high reimbursement figures.
Medical necessity could become another contested area if prosecutors introduce patient files or utilization evidence, although the indictment’s principal narrative emphasizes kickbacks and price misrepresentations instead of alleging that every skin-substitute application was clinically unnecessary or never delivered.
Because complex fraud cases unfold simultaneously in court and public discussion, a carefully documented crisis public-relations management plan can help affected organizations communicate responsibly, protect patient confidentiality, avoid prejudging uncharged individuals, and respond accurately as new filings alter the factual record.
An Indictment Begins the Court Process
McMillan’s indictment marks the beginning of a federal prosecution rather than its conclusion, and the government’s detailed invoices, commission reports, emails, property transactions, and reimbursement figures will still require authentication, contextual explanation, evidentiary rulings, and persuasive presentation before they can support criminal convictions.
For prosecutors, the case tests whether reimbursement-contingent wound-product pricing can be proven as a deliberately concealed kickback structure, while the defense can challenge the government’s interpretation of commercial contracts, claim disclosures, witness accounts, intent, and the source of disputed assets.
For the healthcare industry, the broader warning is already visible: federal investigators are examining not only whether services were delivered, but also who selected products, how prices were reported, when invoices became payable, who shared reimbursements, and whether compensation secretly rewarded federally funded referrals.
Until a jury returns verdicts or another lawful resolution occurs, every accusation against Michael McMillan remains unproven, every charged count remains subject to challenge, and the constitutional presumption of innocence continues to govern this closely watched $268 million healthcare fraud case.
Be First to Comment